Analyst Price Targets — MIRM
Latest News for MIRM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company's stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,586 shares of the company's stock, valued at approximately $9,551,000. Deutsche Bank AG owned 0.13% of Mirum Pharmaceuticals at the end
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIRM.
U.S. House Trading
No House trades found for MIRM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.